Resistance to endocrine therapy (ET) remains a major clinical challenge in the treatment of estrogen receptor-positive (ER+) breast cancer, underscoring the need for novel therapeu
A single-centre retrospective study with modest sample size identifying predictive biomarkers for radioiodine response using immunohistochemistry and mutation analysis; results are encouraging but require validation in an independent cohort before clinical adoption.
Single-centre scRNA-seq descriptive study of 11 tumours with small LT subgroup, identifying immune mechanisms without functional validation or clinical outcome prediction.